levoleucovorin and Rett-Syndrome

levoleucovorin has been researched along with Rett-Syndrome* in 6 studies

Trials

4 trial(s) available for levoleucovorin and Rett-Syndrome

ArticleYear
Folinic acid supplementation in Rett syndrome patients does not influence the course of the disease: a randomized study.
    Journal of child neurology, 2012, Volume: 27, Issue:3

    Rett syndrome is a neurodevelopmental disorder in girls, related to mutations in MECP2 gene. It has been postulated that low 5-methyltetrahydrofolate (5-MTHF) levels are present in cerebrospinal fluid. Folinic acid demonstrated clinical improvement. However, because studies have produced conflicting results, we performed a randomized, double-blind crossover, long-term, follow-up study on folinic acid. Eight Rett syndrome patients received both folinic acid and placebo, for 1 year each. Measurements included plasma folate, 5-MTHF, and clinical outcome scores like Rett Syndrome Motor Behavioral Assessment, Hand Apraxia Scale, and the parental Overall Well-Being Index. In 2 patients, low 5-MTHF levels were present. Folinic acid supplementation increased cerebrospinal fluid 5-MTHF levels, but with no objective evidence of clinical improvement. The Overall Well-Being Index showed a significant difference in favor of folinic acid, not confirmed objectively. In our double-blind randomized study, folinic acid supplementation resulted in increased 5-MTHF levels, but with no objective signs of clinical improvement.

    Topics: Adolescent; Adult; Child; Child, Preschool; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Female; Folic Acid; Humans; Leucovorin; Linear Models; Longitudinal Studies; Methyl-CpG-Binding Protein 2; Mutation; Neurologic Examination; Rett Syndrome; Tetrahydrofolates; Time Factors; Treatment Outcome; Young Adult

2012
Clinical and electroencephalographic effects of folinic acid treatment in Rett syndrome patients.
    Journal of child neurology, 2011, Volume: 26, Issue:6

    Rett syndrome is characterized by the development of stereotypic hand movements and seizures, which are often difficult to treat. Previous studies have shown conflicting results during add-on folinic acid. Here, the authors reevaluate the response to folinic acid in terms of epilepsy control and electroencephalography features. They performed a randomized, placebo-controlled, double-blind crossover trial, with a follow-up of more than 2 years. Twelve girls with Rett syndrome participated, comparable in clinical stage and disease severity. The Rett syndrome patients were given either folinic acid or placebo, for 1 year each. Only 3 girls benefited to some extent: 2 had a reduction and/or decrease in seizures, and all 3 showed some decreased epileptiform activity on electroencephalography during the addition of folinic acid. Despite this, antiepileptic drugs were adjusted. Because the effect of added folinic acid was limited and did not prevent antiepileptic drug increase, the authors do not recommend adding on folinic acid in Rett syndrome girls with epilepsy.

    Topics: Brain Waves; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Electroencephalography; Female; Follow-Up Studies; Humans; Leucovorin; Male; Rett Syndrome; Seizures; Severity of Illness Index; Spectrum Analysis

2011
Evaluation of CSF neurotransmitters and folate in 25 patients with Rett disorder and effects of treatment.
    Brain & development, 2009, Volume: 31, Issue:1

    Rett disorder (RD) is a progressive neurodevelopmental entity caused by mutations in the MECP2 gene. It has been postulated that there are alterations in the levels of certain neurotransmitters and folate in the pathogenesis of this disease. Here we re-evaluated this hypothesis.. We evaluated CSF folate, biogenic amines and pterines in 25 RD patients. Treatment with oral folinic acid was started in those cases with low folate. Patients were clinically evaluated and videotaped up to 6 months after therapy.. CSF folate was below the reference values in 32% of the patients. Six months after treatment no clinical improvement was observed. Three of the four patients with the R294X mutation had increased levels of a dopamine metabolite associated to a particular phenotype. Three patients had low levels of a serotonin metabolite. Two of them were treated with fluoxetine and one showed clinical improvement. No association was observed between CSF folate and these metabolites, after adjusting for the patients age and neopterin levels.. Our results support that folinic acid supplementation has no significant effects on the course of the disease. We report discrete and novel neurotransmitter abnormalities that may contribute to the pathogenesis of RD highlighting the need for further studies on CSF neurotransmitters in clinically and genetically well characterized patients.

    Topics: Administration, Oral; Child; Child, Preschool; DNA Mutational Analysis; Female; Fluoxetine; Folic Acid; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Leucovorin; Methyl-CpG-Binding Protein 2; Mutation; Neurotransmitter Agents; Polymerase Chain Reaction; Rett Syndrome; Seizures; Selective Serotonin Reuptake Inhibitors; Stereotyped Behavior; Treatment Outcome; Vitamin B Complex

2009
Cerebrospinal fluid concentrations of folate, biogenic amines and pterins in Rett syndrome: treatment with folinic acid.
    Neuropediatrics, 2005, Volume: 36, Issue:6

    Previous studies in Rett syndrome (RS) patients suggested various abnormalities in biogenic amines, pterins, and folate values in cerebrospinal fluid (CSF). Our aim was to analyse these metabolites in CSF of 16 RS patients (age range: 2 - 23 years). Biogenic amines, pterins, and 5-methyltetrahydrofolate were measured by HPLC with electrochemical and fluorescence detection.. CSF values of 5-methyltetrahydrofolate were decreased in 8 out of 16 RS patients (average: 53.6 nmol/L; range: 19 - 92) when compared with our reference values (average: 74.6 nmol/L; range: 45 - 127). These eight patients had epilepsy, while 4 out of 16 RS patients who did not have epilepsy showed normal CSF 5-methyltetrahydrofolate concentrations. Values of biogenic amines or pterins were decreased in four of the patients with low values of 5-methyltetrahydrofolate. No correlation was observed between CSF values of 5-methyltetrahydrofolate and pterins, biogenic amines, or age. Supplementation with folinic acid was applied in six out of the eight patients with CSF 5-methyltetrahydrofolate deficiency. An improvement was noticed in all cases.. An important percentage of RS patients showed 5-methyltetrahydrofolate concentrations under the reference values. Therefore, analysis of CSF 5-methyltetrahydrofolate seems advisable in RS, especially in patients with epilepsy and those resistant to antiepileptic drugs.

    Topics: Adolescent; Biogenic Amines; Child; Child, Preschool; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Folic Acid; Humans; Leucovorin; Methyl-CpG-Binding Protein 2; Pteroylpolyglutamic Acids; Rett Syndrome; Statistics, Nonparametric; Vitamin B Complex

2005

Other Studies

2 other study(ies) available for levoleucovorin and Rett-Syndrome

ArticleYear
Spinal fluid 5-methyltetrahydrofolate levels are normal in Rett syndrome.
    Neurology, 2005, Jun-28, Volume: 64, Issue:12

    Topics: Adolescent; Adult; Biomarkers; Blood-Brain Barrier; Brain; Cerebrospinal Fluid; Child; Child, Preschool; Female; Folic Acid; Folic Acid Deficiency; Humans; Leucovorin; Predictive Value of Tests; Reference Values; Rett Syndrome; Tetrahydrofolates; Treatment Outcome

2005
Reduced folate transport to the CNS in female Rett patients.
    Neurology, 2003, Aug-26, Volume: 61, Issue:4

    Previous CSF studies in Rett syndrome suggest reduced turnover of the biogenic monoamines serotonin and dopamine. Because diminished turnover may result from CNS folate depletion, the authors studied transport of folate across the blood-brain barrier.. In four patients with Rett syndrome, the authors measured CSF values of 5-methyltetrahydrofolate (5MTHF), biogenic monoamine end-metabolites, and pterins together with serum and red blood cell folate. In CSF, the overall folate binding capacity by the two soluble folate-binding proteins FBP1 and FBP2 (sFBP) was measured using a radioligand binding method for H3-labeled folate. A specific immunoreactive test (ELISA) detected sFBP1, which normally contributes to 30 to 35% of the total folate binding capacity. Genetic analysis included DNA sequencing of the MECP2, FBP1, and FBP2 genes. Empirical treatment with oral folinic acid was evaluated.. Two patients without and two with mutations of the MECP2 gene had normal values for red blood cell folate, serum folate, homocysteine, and methionine. In CSF, all patients had low values for 5MTHF, neopterin, and the serotonin end-metabolite 5-hydroxyindoleacetic acid (5-HIAA). Genetic analysis of FBP1 and FBP2 genes had normal results. Compared to controls, patients with Rett syndrome had normal immunoreactive sFBP1 in CSF, whereas the total folate binding capacity was disproportionately lowered. Empirical treatment with oral folinic acid normalized 5-MHTF and 5-HIAA levels in CSF, and led to partial clinical improvement.. Irrespective of the MECP2 genotype, 5MTHF transfer to the CNS is reduced in Rett syndrome. Folinic acid supplementation restores 5MTHF levels and serotoninergic turnover. The lowered folate binding capacity of FBP is not explained by a defect of the FBP1 or FBP2 gene, but most likely occurs as a secondary phenomenon in Rett syndrome.

    Topics: Biogenic Monoamines; Biomarkers; Blood-Brain Barrier; Carrier Proteins; Central Nervous System; Child, Preschool; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Leucovorin; Protein Isoforms; Pterins; Receptors, Cell Surface; Rett Syndrome; Sequence Analysis, DNA; Tetrahydrofolates

2003